{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:50:08Z","timestamp":1793346608409,"version":"4.5.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Spinal muscular atrophy (SMA) is a neuromuscular disease caused by mutations in the survival motor neuron gene,\n                      <jats:italic>SMN1<\/jats:italic>\n                      . Loss of\n                      <jats:italic>SMN1<\/jats:italic>\n                      function results in deficiency of the SMN protein leading to motor neuron death, muscle wasting, and progressive loss of motor function. Two disease modifying therapies have been approved for teens and adults in the United States, with many more potential treatments in the drug development pipeline. As treatment options for teens and adults with SMA increase, a validated core set of outcome measures is needed to assess motor function, perceived fatigue, and perceived fatigability. The aim of this study was to determine which type of outcome measures best captures changes in disease status in teens and adults with SMA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the first phase of this two-part study, a working group of key opinion leaders in SMA research and clinical care was surveyed using a modified Delphi method. The working group concluded that a patient-reported outcome measure based on activities of daily living (ADLs) would be the best way to capture changes in function, perceived fatigue, and perceived fatigability that are meaningful to clinicians, as well as teens and adults living with SMA. In the second phase of the study, two discussion groups of adults (non-ambulatory or ambulatory) were interviewed for their perspectives about which ADLs are most important to them, and about how perceived fatigue affects their abilities to perform these ADLs. Both discussion groups prioritized ADLs that related to independence and dignity. Non-ambulatory and ambulatory participants also reported that perceived fatigue and fatigability are a major factor in their ability to perform ADLs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SMA key opinion leaders and adults with SMA agreed that ADLs would be sensitive and impactful outcomes in the assessment of function, perceived fatigue, and perceived fatigability. The findings of this study form a foundation for reaching consensus around a core set of outcome measures for assessing disease status, perceived fatigue, and perceived fatigability in teens and adults with SMA in the U.S.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04047-x","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:09:34Z","timestamp":1760702974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A qualitative, mixed-method approach to reaching consensus on function, fatigue, and fatigability outcomes in teens and adults living with spinal muscular atrophy"],"prefix":"10.1186","volume":"20","author":[{"given":"Jacqueline","family":"Glascock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa T.","family":"Belter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan Moore","family":"Burk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica J.","family":"Tingey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"1","key":"4047_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ppul.10110","volume":"34","author":"JR Bach","year":"2002","unstructured":"Bach JR, Baird JS, Plosky D, Navado J, Weaver B. Spinal muscular atrophy type 1: management and outcomes. Pediatr Pulmonol. 2002;34(1):16\u201322.","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"4047_CR2","first-page":"19","volume":"40","author":"J Borkowska","year":"2002","unstructured":"Borkowska J, Rudnik-Schoneborn S, Hausmanowa-Petrusewicz I, Zerres K. Early infantile form of spinal muscular atrophy (werdnig-hoffmann disease) with prolonged survival. Folia Neuropathol. 2002;40(1):19\u201326.","journal-title":"Folia Neuropathol"},{"issue":"5","key":"4047_CR3","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1542\/peds.2004-0668","volume":"114","author":"BH Chung","year":"2004","unstructured":"Chung BH, Wong VC, Ip P. Spinal muscular atrophy: survival pattern and functional status. Pediatrics. 2004;114(5):e548\u201353.","journal-title":"Pediatrics"},{"key":"4047_CR4","doi-asserted-by":"crossref","unstructured":"Milligan JN, Blasco-Perez L, Costa-Roger M, Codina-Sola M, Tizzano EF. Recommendations for interpreting and reporting silent carrier and disease-modifying variants in SMAtesting workflows. Genes (Basel). 2022;13(9):1657.","DOI":"10.3390\/genes13091657"},{"key":"4047_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S239603","volume":"14","author":"MC Keinath","year":"2021","unstructured":"Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: Mutations, testing, and clinical relevance. Appl Clin Genet. 2021;14:11\u201325.","journal-title":"Appl Clin Genet"},{"key":"4047_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","volume":"21","author":"B Wirth","year":"2020","unstructured":"Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet. 2020;21:231\u201361.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"21","key":"4047_CR7","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1007\/s00018-018-2849-1","volume":"75","author":"H Chaytow","year":"2018","unstructured":"Chaytow H, Huang YT, Gillingwater TH, Faller KME. The role of survival motor neuron protein (SMN) in protein homeostasis. Cell Mol Life Sci. 2018;75(21):3877\u201394.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"4047_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","volume":"1860","author":"RN Singh","year":"2017","unstructured":"Singh RN, Howell MD, Ottesen EW, Singh NN. Diverse role of survival motor neuron protein. Biochim Biophys Acta Gene Regul Mech. 2017;1860(3):299\u2013315.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"8","key":"4047_CR9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","volume":"6","author":"DD Coovert","year":"1997","unstructured":"Coovert DD, Le TT, McAndrew PE, et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997;6(8):1205\u201314.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"4047_CR10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u201391.","journal-title":"Ann Neurol"},{"issue":"5","key":"4047_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","volume":"52","author":"K Zerres","year":"1995","unstructured":"Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52(5):518\u201323.","journal-title":"Arch Neurol"},{"issue":"9","key":"4047_CR12","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00415-008-0929-0","volume":"255","author":"S Piepers","year":"2008","unstructured":"Piepers S, van den Berg LH, Brugman F, et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol. 2008;255(9):1400\u20134.","journal-title":"J Neurol"},{"issue":"2","key":"4047_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/acn3.51281","volume":"8","author":"M Annoussamy","year":"2021","unstructured":"Annoussamy M, Seferian AM, Daron A, et al. Natural history of type 2 and 3 spinal muscular atrophy: 2-year NATHIS-SMA study. Ann Clin Transl Neurol. 2021;8(2):359\u201373.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"4047_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13023-022-02455-x","volume":"17","author":"C Cances","year":"2022","unstructured":"Cances C, Vlodavets D, Comi GP, et al. Natural history of type 1 spinal muscular atrophy: A retrospective, global, multicenter study. Orphanet J Rare Dis. 2022;17(1):300.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4047_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","volume":"15","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Lucibello S, Perulli M, et al. Longitudinal natural history of type I spinal muscular atrophy: A critical review. Orphanet J Rare Dis. 2020;15(1):84.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4047_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-022-02227-7","volume":"17","author":"ES Veldhoen","year":"2022","unstructured":"Veldhoen ES, Wijngaarde CA, Hulzebos EHJ, et al. Natural history of respiratory muscle strength in spinal muscular atrophy: A prospective National cohort study. Orphanet J Rare Dis. 2022;17(1):70.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"4047_CR17","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137.","journal-title":"Neurology"},{"issue":"6","key":"4047_CR18","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/archneurol.2010.373","volume":"68","author":"P Kaufmann","year":"2011","unstructured":"Kaufmann P, McDermott MP, Darras BT, et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol. 2011;68(6):779\u201386.","journal-title":"Arch Neurol"},{"issue":"8","key":"4047_CR19","doi-asserted-by":"publisher","first-page":"e696","DOI":"10.1212\/WNL.0000000000006050","volume":"91","author":"M Pane","year":"2018","unstructured":"Pane M, Palermo C, Messina S, et al. An observational study of functional abilities in infants, children, and adults with type 1 SMA. Neurology. 2018;91(8):e696\u2013703.","journal-title":"Neurology"},{"key":"4047_CR20","doi-asserted-by":"publisher","first-page":"104851","DOI":"10.1016\/j.earlhumdev.2019.104851","volume":"138","author":"EF Tizzano","year":"2019","unstructured":"Tizzano EF. Treating neonatal spinal muscular atrophy: A 21st century success story? Early Hum Dev. 2019;138:104851.","journal-title":"Early Hum Dev"},{"issue":"2","key":"4047_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/mus.27261","volume":"64","author":"BH Lee","year":"2021","unstructured":"Lee BH, Waldrop MA, Connolly AM, Ciafaloni E. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Muscle Nerve. 2021;64(2):153\u20135.","journal-title":"Muscle Nerve"},{"issue":"8","key":"4047_CR22","doi-asserted-by":"publisher","first-page":"100725","DOI":"10.1016\/j.xcrm.2022.100725","volume":"3","author":"AAL Motyl","year":"2022","unstructured":"Motyl AAL, Gillingwater TH. Timing is everything: clinical evidence supports pre-symptomatic treatment for spinal muscular atrophy. Cell Rep Med. 2022;3(8):100725.","journal-title":"Cell Rep Med"},{"key":"4047_CR23","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","volume":"15","author":"T Dangouloff","year":"2019","unstructured":"Dangouloff T, Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag. 2019;15:1153\u201361.","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"4047_CR24","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/ana.26788","volume":"94","author":"M Ricci","year":"2023","unstructured":"Ricci M, Cicala G, Capasso A, et al. Clinical phenotype of pediatric and adult patients with spinal muscular atrophy with four SMN2 copies: are they really all stable? Ann Neurol. 2023;94(6):1126\u201335.","journal-title":"Ann Neurol"},{"issue":"2","key":"4047_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/ene.14587","volume":"28","author":"PVS Souza","year":"2021","unstructured":"Souza PVS, Pinto W, Ricarte A, et al. Clinical and radiological profile of patients with spinal muscular atrophy type 4. Eur J Neurol. 2021;28(2):609\u201319.","journal-title":"Eur J Neurol"},{"issue":"2","key":"4047_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JND-190468","volume":"7","author":"J Glascock","year":"2020","unstructured":"Glascock J, Sampson J, Connolly AM, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. J Neuromuscul Dis. 2020;7(2):97\u2013100.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"4047_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13023-021-01771-y","volume":"16","author":"A Lusakowska","year":"2021","unstructured":"Lusakowska A, Jedrzejowska M, Kaminska A, et al. Observation of the natural course of type 3 spinal muscular atrophy: data from the Polish registry of spinal muscular atrophy. Orphanet J Rare Dis. 2021;16(1):150.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"4047_CR28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman RI, Wijngaarde CA, Stam M, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4. Eur J Neurol. 2018;25(3):512\u20138.","journal-title":"Eur J Neurol"},{"issue":"4","key":"4047_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ajmg.10425","volume":"110","author":"S Ogino","year":"2002","unstructured":"Ogino S, Leonard DG, Rennert H, Ewens WJ, Wilson RB. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet. 2002;110(4):301\u20137.","journal-title":"Am J Med Genet"},{"issue":"4","key":"4047_CR30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","volume":"88","author":"RI Wadman","year":"2017","unstructured":"Wadman RI, Stam M, Gijzen M, et al. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0\u20134. J Neurol Neurosurg Psychiatry. 2017;88(4):365\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"4047_CR31","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/0883073807305673","volume":"22","author":"BS Russman","year":"2007","unstructured":"Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol. 2007;22(8):946\u201351.","journal-title":"J Child Neurol"},{"issue":"1","key":"4047_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1\u201313.","journal-title":"J Neuromuscul Dis"},{"key":"4047_CR33","unstructured":"Spinraza prescribing information. Cambridge: Biogen. 2016. Available from: https:\/\/www.spinraza.com\/content\/dam\/commercial\/spinraza\/caregiver\/en_us\/pdf\/spinraza-prescribing-information.pdf"},{"key":"4047_CR34","unstructured":"Zolgensma prescribing information. Bannockburn: AveXis Inc. 2019. Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/zolgensma.pdf"},{"key":"4047_CR35","unstructured":"Evrysdi prescribing information. San Francisco: Genentech. 2020. Available from: https:\/\/www.gene.com\/download\/pdf\/evrysdi_prescribing.pdf"},{"issue":"6","key":"4047_CR36","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/acn3.51562","volume":"9","author":"RS Finkel","year":"2022","unstructured":"Finkel RS, Ryan MM, Pascual Pascual SI, et al. Scientific rationale for a higher dose of Nusinersen. Ann Clin Transl Neurol. 2022;9(6):819\u201329.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"4047_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, G\u00fcnther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: A non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19(4):317\u201325.","journal-title":"Lancet Neurol"},{"key":"4047_CR38","doi-asserted-by":"crossref","unstructured":"Osmanovic A, Schreiber-Katz O, Petri S. Nusinersen wearing-off in adult 5q-spinal muscular atrophy patients. Brain Sci. 2021;11(3):367.","DOI":"10.3390\/brainsci11030367"},{"key":"4047_CR39","unstructured":"Cure SMA, SMA Drug Pipeline. 2024. Available from: https:\/\/www.curesma.org\/sma-drug-pipeline\/"},{"issue":"11","key":"4047_CR40","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1002\/acn3.51889","volume":"10","author":"CM Proud","year":"2023","unstructured":"Proud CM, Mercuri E, Finkel RS, et al. Combination disease-modifying treatment in spinal muscular atrophy: A proposed classification. Ann Clin Transl Neurol. 2023;10(11):2155\u201360.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"4047_CR41","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/mus.27034","volume":"62","author":"Y Harada","year":"2020","unstructured":"Harada Y, Rao VK, Arya K, et al. Combination molecular therapies for type 1 spinal muscular atrophy. Muscle Nerve. 2020;62(4):550\u20134.","journal-title":"Muscle Nerve"},{"key":"4047_CR42","doi-asserted-by":"crossref","unstructured":"Jha NN, Kim JK, Her YR, Monani UR. Muscle: an independent contributor to the neuromuscular spinal muscular atrophy disease phenotype. JCI Insight. 2023;8(18):e171878.","DOI":"10.1172\/jci.insight.171878"},{"key":"4047_CR43","unstructured":"United States Food and Drug Administration. Focus area: Patient-reported outcomes and other clinical outcome assessments. 2022. Available from: https:\/\/www.fda.gov\/science-research\/focus-areas-regulatory-science-report\/focus-area-patient-reported-outcomes-and-other-clinical-outcome-assessments"},{"issue":"4","key":"4047_CR44","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3233\/JND-200617","volume":"8","author":"J Slayter","year":"2021","unstructured":"Slayter J, Hodgkinson V, Lounsberry J, et al. A Canadian adult spinal muscular atrophy outcome measures toolkit: results of a National consensus using a modified Delphi method. J Neuromuscul Dis. 2021;8(4):579\u201388.","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"4047_CR45","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3233\/JND-221595","volume":"10","author":"J Slayter","year":"2023","unstructured":"Slayter J, Casey L, O\u2019Connell C. Patient reported outcome measures in adult spinal muscular atrophy: A scoping review and graphical visualization of the evidence. J Neuromuscul Dis. 2023;10(2):239\u201350.","journal-title":"J Neuromuscul Dis"},{"key":"4047_CR46","doi-asserted-by":"crossref","unstructured":"Belter L, Peterson I, Jarecki J. Evaluating perceived fatigue within an adult spinal muscular atrophy population. Neurol Ther. 2023; 12(6):2161-2175.","DOI":"10.1007\/s40120-023-00552-y"},{"issue":"3","key":"4047_CR47","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s00415-020-10227-5","volume":"268","author":"C Binz","year":"2021","unstructured":"Binz C, Schreiber-Katz O, Kumpe M, et al. An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving Nusinersen treatment. J Neurol. 2021;268(3):950\u201362.","journal-title":"J Neurol"},{"issue":"1","key":"4047_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JND-180342","volume":"6","author":"S Dunaway Young","year":"2019","unstructured":"Dunaway Young S, Montes J, Kramer SS, Podwika B, Rao AK, De Vivo DC. Perceived fatigue in spinal muscular atrophy: A pilot study. J Neuromuscul Dis. 2019;6(1):109\u201317.","journal-title":"J Neuromuscul Dis"},{"issue":"8","key":"4047_CR49","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s00415-020-09847-8","volume":"267","author":"A Osmanovic","year":"2020","unstructured":"Osmanovic A, Ranxha G, Kumpe M, et al. Treatment expectations and patient-reported outcomes of Nusinersen therapy in adult spinal muscular atrophy. J Neurol. 2020;267(8):2398\u2013407.","journal-title":"J Neurol"},{"issue":"1","key":"4047_CR50","first-page":"1","volume":"43","author":"O Crisafulli","year":"2024","unstructured":"Crisafulli O, Berardinelli A, D\u2019Antona G. Fatigue in spinal muscular atrophy: A fundamental open issue. Acta Myol. 2024;43(1):1\u20137.","journal-title":"Acta Myol"},{"key":"4047_CR51","doi-asserted-by":"crossref","unstructured":"Rodriguez-Torres RS, Uher D, Gay EL et al. Measuring fatigue and fatigability in spinal muscular atrophy (SMA): challenges and opportunities. J Clin Med. 2023;12(10):3458.","DOI":"10.3390\/jcm12103458"},{"key":"4047_CR52","doi-asserted-by":"crossref","unstructured":"Stolte B, Neuhoff S, Lipka J et al. Performance fatigability in adults with spinal muscular atrophy treated long-term with Nusinersen. Muscle Nerve. 2024;70(6):1223-1229.","DOI":"10.1002\/mus.28269"},{"issue":"1","key":"4047_CR53","first-page":"221436022413133","volume":"12","author":"R Rodriguez-Torres","year":"2025","unstructured":"Rodriguez-Torres R, Kanner CH, Gay EL, et al. Development of the SMA EFFORT: A new approach to characterize perceived physical fatigability in spinal muscular atrophy. J Neuromuscul Dis. 2025;12(1):22143602241313326.","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"4047_CR54","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s11136-013-0565-8","volume":"23","author":"U Werlauff","year":"2014","unstructured":"Werlauff U, H\u00f8jberg A, Firla-Holme R, Steffensen BF, Vissing J. Fatigue in patients with spinal muscular atrophy type II and congenital myopathies: evaluation of the fatigue severity scale. Qual Life Research: Int J Qual Life Aspects Treat Care Rehabilitation. 2014;23(5):1479\u201388.","journal-title":"Qual Life Research: Int J Qual Life Aspects Treat Care Rehabilitation"},{"issue":"3","key":"4047_CR55","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/acn3.51520","volume":"9","author":"C Binz","year":"2022","unstructured":"Binz C, Osmanovic A, Thomas NH, et al. Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy. Ann Clin Transl Neurol. 2022;9(3):351\u201362.","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"4047_CR56","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mus.27223","volume":"63","author":"CE Zizzi","year":"2021","unstructured":"Zizzi CE, Luebbe E, Mongiovi P, et al. The spinal muscular atrophy health index: A novel outcome for measuring how a patient feels and functions. Muscle Nerve. 2021;63(6):837\u201344.","journal-title":"Muscle Nerve"},{"issue":"4","key":"4047_CR57","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.neurop.2022.06.008","volume":"2","author":"MC Domine","year":"2022","unstructured":"Domine MC, de Lemus M, Castellano IP, \u00d1ungo-Garz\u00f3n NC, Sevilla-Mantec\u00f3n T, V\u00e1zquez-Costa JF. Physical fatigue and perceived fatigability in adolescents and adults with spinal muscular atrophy: A pilot study. Neurol Perspect. 2022;2(4):199\u2013208.","journal-title":"Neurol Perspect"},{"issue":"1","key":"4047_CR58","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40120-022-00411-2","volume":"12","author":"JF V\u00e1zquez-Costa","year":"2023","unstructured":"V\u00e1zquez-Costa JF, Branas-Pampill\u00f3n M, Medina-Cantillo J, et al. Validation of a set of instruments to assess patient- and caregiver-oriented measurements in spinal muscular atrophy: results of the SMA-TOOL study. Neurol Ther. 2023;12(1):89\u2013105.","journal-title":"Neurol Ther"},{"issue":"6","key":"4047_CR59","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s40120-023-00552-y","volume":"12","author":"L Belter","year":"2023","unstructured":"Belter L, Peterson I, Jarecki J. Evaluating perceived fatigue within an adult spinal muscular atrophy population. Neurol Ther. 2023;12(6):2161\u201375.","journal-title":"Neurol Ther"},{"key":"4047_CR60","unstructured":"Belter L, Whitmire S, Welsh E, Schroth M. State of SMA: 2023 Report. 2024 May 6, 2024."},{"issue":"1","key":"4047_CR61","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1186\/s12913-022-08694-9","volume":"22","author":"L Benning","year":"2022","unstructured":"Benning L, Das-Gupta Z, Sousa Fialho L, Wissig S, Tapela N, Gaunt S. Balancing adaptability and standardisation: insights from 27 routinely implemented ICHOM standard sets. BMC Health Serv Res. 2022;22(1):1424.","journal-title":"BMC Health Serv Res"},{"key":"4047_CR62","unstructured":"Cure SMA. 2024. Available from: https:\/\/www.curesma.org\/"},{"issue":"2","key":"4047_CR63","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3233\/JND-170292","volume":"5","author":"L Belter","year":"2018","unstructured":"Belter L, Cook SF, Crawford TO, et al. An overview of the cure SMA membership database: highlights of key demographic and clinical characteristics of SMA members. J Neuromuscul Dis. 2018;5(2):167\u201376.","journal-title":"J Neuromuscul Dis"},{"issue":"9","key":"4047_CR64","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1007\/s00415-023-11787-y","volume":"270","author":"HS Lapp","year":"2023","unstructured":"Lapp HS, Freigang M, Hagenacker T, Weiler M, Wurster CD, G\u00fcnther R. Biomarkers in 5q-associated spinal muscular atrophy: A narrative review. J Neurol. 2023;270(9):4157\u201378.","journal-title":"J Neurol"},{"issue":"5","key":"4047_CR65","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3233\/JND-230054","volume":"10","author":"J Glascock","year":"2023","unstructured":"Glascock J, Darras BT, Crawford TO, et al. Identifying biomarkers of spinal muscular atrophy for further development. J Neuromuscul Dis. 2023;10(5):937\u201354.","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"4047_CR66","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s13760-022-02028-6","volume":"123","author":"M Gavriilaki","year":"2023","unstructured":"Gavriilaki M, Papaliagkas V, Stamperna A, et al. Biomarkers of therapeutic efficacy in adolescents and adults with 5q spinal muscular atrophy: A systematic review. Acta Neurol Belgica. 2023;123(5):1735\u201345.","journal-title":"Acta Neurol Belgica"},{"key":"4047_CR67","unstructured":"Burk MFM, Professions RMUH. A new functional scale for spinal muscular atrophy: development and validation of the functional ability scale for evolving SMA (EVOLVE-SMA) 2024."},{"issue":"2","key":"4047_CR68","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1474-4422(23)00419-2","volume":"23","author":"CJJ Yeo","year":"2024","unstructured":"Yeo CJJ, Tizzano EF, Darras BT. Challenges and opportunities in spinal muscular atrophy therapeutics. Lancet Neurol. 2024;23(2):205\u201318.","journal-title":"Lancet Neurol"},{"issue":"1","key":"4047_CR69","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40120-023-00571-9","volume":"13","author":"P Rebollo","year":"2024","unstructured":"Rebollo P, Garc\u00eda-L\u00f3pez S, Povedano M, et al. Design and validation of a clinical outcome measure for adolescents and adult patients with spinal muscular atrophy: SMA life study protocol. Neurol Ther. 2024;13(1):233\u201349.","journal-title":"Neurol Ther"},{"issue":"1","key":"4047_CR70","doi-asserted-by":"publisher","first-page":"e16099","DOI":"10.1111\/ene.16099","volume":"31","author":"T Kessler","year":"2024","unstructured":"Kessler T, Sam G, Wick W, Weiler M. Evaluation of Risdiplam efficacy in 5q spinal muscular atrophy: A systematic comparison of electrophysiologic with clinical outcome measures. Eur J Neurol. 2024;31(1):e16099.","journal-title":"Eur J Neurol"},{"key":"4047_CR71","doi-asserted-by":"crossref","unstructured":"Coratti G, Bovis F, Pera MC et al. Determining minimal clinically important differences in the Hammersmith functional motor scale expanded for untreated spinal muscular atrophy patients: an international study. Eur J Neurol. 2024;31:e16309.","DOI":"10.1111\/ene.16309"},{"issue":"5","key":"4047_CR72","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1007\/s00415-020-10332-5","volume":"268","author":"G Querin","year":"2021","unstructured":"Querin G, Lenglet T, Debs R, et al. Development of new outcome measures for adult SMA type III and IV: A multimodal longitudinal study. J Neurol. 2021;268(5):1792\u2013802.","journal-title":"J Neurol"},{"issue":"3","key":"4047_CR73","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.nmd.2020.12.006","volume":"31","author":"CG Konersman","year":"2021","unstructured":"Konersman CG, Ewing E, Yaszay B, Naheedy J, Murphy S, Skalsky A. Nusinersen treatment of older children and adults with spinal muscular atrophy. Neuromuscul Disord. 2021;31(3):183\u201393.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"4047_CR74","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JND-221519","volume":"10","author":"KJ Krosschell","year":"2023","unstructured":"Krosschell KJ, Brown L, Hoffman K, et al. Longitudinal assessment of timed function tests in ambulatory individuals with SMA treated with Nusinersen. J Neuromuscul Dis. 2023;10(3):337\u201348.","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"4047_CR75","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.nmd.2021.08.010","volume":"32","author":"KJ Krosschell","year":"2022","unstructured":"Krosschell KJ, Townsend EL, Kiefer M, et al. Natural history of 10-meter walk\/run test performance in spinal muscular atrophy: A longitudinal analysis. Neuromuscul Disord. 2022;32(2):125\u201334.","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"4047_CR76","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","volume":"270","author":"M Oskoui","year":"2023","unstructured":"Oskoui M, Day JW, Deconinck N, et al. Two-year efficacy and safety of Risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol. 2023;270(5):2531\u201346.","journal-title":"J Neurol"},{"issue":"11","key":"4047_CR77","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.nmd.2023.07.008","volume":"33","author":"TM Perumal","year":"2023","unstructured":"Perumal TM, Wolf D, Berchtold D, et al. Digital measures of respiratory and upper limb function in spinal muscular atrophy: Design, feasibility, reliability, and preliminary validity of a smartphone sensor-based assessment suite. Neuromuscul Disord. 2023;33(11):845\u201355.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"4047_CR78","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/mus.26769","volume":"61","author":"A Veerapandiyan","year":"2020","unstructured":"Veerapandiyan A, Eichinger K, Guntrum D, et al. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience. Muscle Nerve. 2020;61(2):222\u20136.","journal-title":"Muscle Nerve"},{"issue":"3","key":"4047_CR79","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3233\/JND-190453","volume":"7","author":"CJJ Yeo","year":"2020","unstructured":"Yeo CJJ, Simeone SD, Townsend EL, Zhang RZ, Swoboda KJ. Prospective cohort study of Nusinersen treatment in adults with spinal muscular atrophy. J Neuromuscul Dis. 2020;7(3):257\u201368.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"4047_CR80","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13023-024-03524-z","volume":"20","author":"J Zang","year":"2025","unstructured":"Zang J, Weiss D, Dumitrascu C, et al. Maximal mouth opening in infants and toddlers with spinal muscular atrophy: A prospective controlled study. Orphanet J Rare Dis. 2025;20(1):24.","journal-title":"Orphanet J Rare Dis"},{"key":"4047_CR81","doi-asserted-by":"publisher","first-page":"847786","DOI":"10.3389\/fneur.2022.847786","volume":"13","author":"A Berardi","year":"2022","unstructured":"Berardi A, Conte A, Cimmino L, et al. Evaluation of the psychometric properties of the health assessment questionnaire (HAQ) in a population of individuals with multiple sclerosis. Front Neurol. 2022;13:847786.","journal-title":"Front Neurol"},{"issue":"2","key":"4047_CR82","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/archneur.1996.00550020045014","volume":"53","author":"The ALS CNTF treatment study (ACTS) phase I-II study group","year":"1996","unstructured":"The ALS CNTF treatment study (ACTS) phase I-II study group. The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol. 1996;53(2):141\u20137.","journal-title":"Arch Neurol"},{"key":"4047_CR83","doi-asserted-by":"publisher","first-page":"103033","DOI":"10.1016\/j.ctim.2024.103033","volume":"81","author":"S Peng","year":"2024","unstructured":"Peng S, Meng L, Fang R, et al. Current state of research on exercise for the treatment of myasthenia gravis: A scoping review. Complement Ther Med. 2024;81:103033.","journal-title":"Complement Ther Med"},{"key":"4047_CR84","doi-asserted-by":"publisher","first-page":"120059","DOI":"10.1016\/j.jns.2021.120059","volume":"432","author":"D Trundell","year":"2022","unstructured":"Trundell D, Skalicky A, Staunton H, et al. Development of the SMA independence scale-upper limb module (smais-ulm): A novel scale for individuals with type 2 and non-ambulant type 3 SMA. J Neurol Sci. 2022;432:120059.","journal-title":"J Neurol Sci"},{"key":"4047_CR85","doi-asserted-by":"crossref","unstructured":"Lefton-Greif MA, Belter L, Jarecki J et al. Patient-reported assessment of bulbar function in spinal muscular atrophy (SMA): validation of a self-report scale. J Neuromuscul Dis. 2025;12:22143602251325741.","DOI":"10.1177\/22143602251325741"},{"issue":"1","key":"4047_CR86","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3233\/JND-210735","volume":"9","author":"KA Rich","year":"2022","unstructured":"Rich KA, Fox A, Yalvac M, et al. Neurofilament levels in CSF and serum in an adult SMA cohort treated with Nusinersen. J Neuromuscul Dis. 2022;9(1):111\u20139.","journal-title":"J Neuromuscul Dis"},{"key":"4047_CR87","doi-asserted-by":"crossref","unstructured":"Andr\u00e9s-Benito P, V\u00e1zquez-Costa JF, \u00d1ungo Garz\u00f3n NC et al. Neurodegeneration biomarkers in adult spinal muscular atrophy (SMA) patients treated with Nusinersen. Int J Mol Sci. 2024;25(7):3810.","DOI":"10.3390\/ijms25073810"},{"issue":"3","key":"4047_CR88","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.nmd.2021.12.005","volume":"32","author":"M Gavriilaki","year":"2022","unstructured":"Gavriilaki M, Moschou M, Papaliagkas V, et al. Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: A systematic review and meta-analysis. Neuromuscul Disord. 2022;32(3):185\u201394.","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"4047_CR89","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","volume":"74","author":"J Montes","year":"2010","unstructured":"Montes J, McDermott MP, Martens WB, et al. Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology. 2010;74(10):833\u20138.","journal-title":"Neurology"},{"issue":"5","key":"4047_CR90","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/acn3.51353","volume":"8","author":"J Montes","year":"2021","unstructured":"Montes J, Goodwin AM, McDermott MP, et al. Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy. Ann Clin Transl Neurol. 2021;8(5):1086\u201395.","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"4047_CR91","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/mus.24670","volume":"52","author":"J Montes","year":"2015","unstructured":"Montes J, Glanzman AM, Mazzone ES, et al. Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy. Muscle Nerve. 2015;52(6):942\u20137.","journal-title":"Muscle Nerve"},{"issue":"6","key":"4047_CR92","doi-asserted-by":"publisher","first-page":"e0199657","DOI":"10.1371\/journal.pone.0199657","volume":"13","author":"J Montes","year":"2018","unstructured":"Montes J, McDermott MP, Mirek E, et al. Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. PLoS ONE. 2018;13(6):e0199657.","journal-title":"PLoS ONE"},{"issue":"5","key":"4047_CR93","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mus.25120","volume":"54","author":"S Dunaway Young","year":"2016","unstructured":"Dunaway Young S, Montes J, Kramer SS, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016;54(5):836\u201342.","journal-title":"Muscle Nerve"},{"issue":"1","key":"4047_CR94","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JND-221600","volume":"10","author":"A Pechmann","year":"2023","unstructured":"Pechmann A, Behrens M, D\u00f6rnbrack K, et al. Improvements in walking distance during Nusinersen treatment - a prospective 3-year smartcare registry study. J Neuromuscul Dis. 2023;10(1):29\u201340.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"4047_CR95","doi-asserted-by":"publisher","first-page":"11069","DOI":"10.1038\/s41598-020-68051-w","volume":"10","author":"K Kizina","year":"2020","unstructured":"Kizina K, Stolte B, Totzeck A, et al. Fatigue in adults with spinal muscular atrophy under treatment with Nusinersen. Sci Rep. 2020;10(1):11069.","journal-title":"Sci Rep"},{"issue":"4","key":"4047_CR96","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/mus.26633","volume":"60","author":"J Montes","year":"2019","unstructured":"Montes J, Dunaway Young S, Mazzone ES, et al. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle Nerve. 2019;60(4):409\u201314.","journal-title":"Muscle Nerve"},{"issue":"6","key":"4047_CR97","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/mus.28269","volume":"70","author":"B Stolte","year":"2024","unstructured":"Stolte B, Neuhoff S, Lipka J, et al. Performance fatigability in adults with spinal muscular atrophy treated long-term with Nusinersen. Muscle Nerve. 2024;70(6):1223\u20139.","journal-title":"Muscle Nerve"},{"key":"4047_CR98","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.clinph.2023.06.024","volume":"154","author":"LE Habets","year":"2023","unstructured":"Habets LE, Bartels B, Jeneson JAL, et al. Enhanced low-threshold motor unit capacity during endurance tasks in patients with spinal muscular atrophy using pyridostigmine. Clin Neurophysiology: Official J Int Federation Clin Neurophysiol. 2023;154:100\u20136.","journal-title":"Clin Neurophysiology: Official J Int Federation Clin Neurophysiol"},{"issue":"3","key":"4047_CR99","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.clinph.2020.11.044","volume":"132","author":"LE Habets","year":"2021","unstructured":"Habets LE, Bartels B, de Groot JF, et al. Motor unit reserve capacity in spinal muscular atrophy during fatiguing endurance performance. Clin Neurophysiology: Official J Int Federation Clin Neurophysiol. 2021;132(3):800\u20137.","journal-title":"Clin Neurophysiology: Official J Int Federation Clin Neurophysiol"},{"issue":"1","key":"4047_CR100","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13023-020-1348-2","volume":"15","author":"B Bartels","year":"2020","unstructured":"Bartels B, de Groot JF, Habets LE, et al. Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests. Orphanet J Rare Dis. 2020;15(1):75.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4047_CR101","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12883-024-03725-w","volume":"24","author":"JA Yoon","year":"2024","unstructured":"Yoon JA, Jeong Y, Lee J, Lee DJ, Lee KN, Shin YB. Improvement in functional motor scores in patients with non-ambulatory spinal muscle atrophy during Nusinersen treatment in South korea: A single center study. BMC Neurol. 2024;24(1):210.","journal-title":"BMC Neurol"},{"key":"4047_CR102","doi-asserted-by":"crossref","unstructured":"Tang WJ, Gu B, Montalvo S et al. Assessing the assisted six-minute cycling test as a measure of endurance in non-ambulatory patients with spinal muscular atrophy (SMA). J Clin Med. 2023;12(24):7582.","DOI":"10.3390\/jcm12247582"},{"issue":"3","key":"4047_CR103","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1212\/CPJ.0000000000001033","volume":"11","author":"T Duong","year":"2021","unstructured":"Duong T, Wolford C, McDermott MP, et al. Nusinersen treatment in adults with spinal muscular atrophy. Neurol Clin Pract. 2021;11(3):e317\u201327.","journal-title":"Neurol Clin Pract"},{"issue":"6","key":"4047_CR104","doi-asserted-by":"publisher","first-page":"e845","DOI":"10.1212\/WNL.0000000000011230","volume":"96","author":"B Bartels","year":"2021","unstructured":"Bartels B, de Groot JF, Habets LE, et al. Correlates of fatigability in patients with spinal muscular atrophy. Neurology. 2021;96(6):e845\u201352.","journal-title":"Neurology"},{"issue":"4","key":"4047_CR105","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S, et al. Safety and treatment effects of Nusinersen in longstanding adult 5q-SMA type 3 - a prospective observational study. J Neuromuscul Dis. 2019;6(4):453\u201365.","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"4047_CR106","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/03009740801914868","volume":"37","author":"M Mattsson","year":"2008","unstructured":"Mattsson M, M\u00f6ller B, Lundberg I, Gard G, Bostr\u00f6m C. Reliability and validity of the fatigue severity scale in Swedish for patients with systemic lupus erythematosus. Scand J Rheumatol. 2008;37(4):269\u201377.","journal-title":"Scand J Rheumatol"},{"key":"4047_CR107","doi-asserted-by":"crossref","unstructured":"Mazzella A, Cruz R, Belter L et al. Assessing perspectives of disease burden and clinically meaningful changes using the spinal muscular atrophy health index in adolescents and young adults. Muscle Nerve. 2022;66(3):276-281.","DOI":"10.1002\/mus.27644"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04047-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04047-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04047-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:03:31Z","timestamp":1760706211000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04047-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4047"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04047-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6917745\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior to initiation, WIRB-Copernicus Group Institutional Review Board (WCG IRB) reviewed and approved the study (IRB Tracking Number: 20226344). All respondents were informed via the informed consent document that findings may be published. Only de-identified results are included within the manuscript. All procedures performed involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"519"}}